San Antonio River Walk

San Antonio – It’s time to switch horses and focus on the annual meeting of the San Antonio Breast Cancer Symposium (SABCS).

There have been many exciting developments in the HER2-positive niche and this meeting is no different in terms of new agents with promising (and some not so promising) to discuss.

We take a look at the tucatinib and trastuzumab deruxtecan data and put them in context because there are some nuances involved in both that need careful consideration.

Curious to find out more about the latest breast cancer data and get a heads up on additional insights from our SABCS commentary?Subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers